Project Grant R21AG101899
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $421K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New Orleans, LA 70112, USA
Similar Awards
- The National Institute on Aging awarded the University of Massachusetts Medical School $452,783 on September 1, 2026, under the Aging Research program (CFDA 93.866) to develop genetically encoded intrabodies that inhibit individual enzymatic domains of retrotransposons in order to define retrotransposon function in synaptic development. The project addresses a critical gap in functional genomics: traditional loss-of-function approaches such as gene knockout and RNA interference cannot decouple...
- The National Institute on Aging awarded the University of Texas Health Science Center at Houston $421,225 on July 1, 2026, under the Aging Research program (CFDA 93.866) to dissect the regulatory mechanism for low-density lipoprotein receptor-related protein 1 using Drosophila vitellogenic oocytes as an in vivo model. The research addresses how LRP1 and related lipid transport receptors regulate amyloid-beta production and clearance and interact with apolipoprotein E4, a primary genetic risk...
- The National Institute on Aging awarded $427,625 to The Washington University on September 1, 2026, under the Aging Research program (CFDA 93.866) to probe cerebellar cortex computations in Alzheimer's disease. The work examines cerebellar nodulus and uvula function in two Alzheimer's disease mouse models—APP/PS1 and 3XTG-AD—at 3, 6, and 12 months of disease progression to assess how hallmarks of Alzheimer's disease contribute to cerebellar dysfunction. The project tests the hypothesis that...
- The National Institute on Aging awarded Brown University $489,408 under Project Grant R01AG094809 on August 1, 2026, to investigate the mechanisms by which the human LINE-1 retrotransposon contributes to aging-related inflammation and senescence. The funded research examines LINE-1's dual activity in driving sterile inflammation and the senescence-associated secretory program (SASP) through two primary investigative pathways: cytosolic cDNA synthesis that activates innate immune signaling via...
- The National Institute on Aging awarded the University of Virginia $583,815 on August 15, 2026, under the Aging Research program (CFDA 93.866) to support research into oligodendrocyte lineage dysfunction during aging and Alzheimer's disease. The project aims to understand how myelin loss—a pathology common to both aging and Alzheimer's disease—develops in the central nervous system and to identify therapeutic targets for cognitive impairment. The research focuses on oligodendrocyte precursor...
- The National Institute on Aging, part of the Department of Health and Human Services, awarded Tulane University $874,974 on September 1, 2026, under the Aging Research program (CFDA 93.866) to study the effects of CSF1R blockade on brain aging and HIV-associated neurocognitive disorder using a macaque model. The project examines how neuroinflammation, myeloid dysregulation, and blood-brain barrier decline drive cognitive impairment in aging and HIV infection. The research uses a macaque model...
- The National Institute on Aging awarded Duke University $1.597 million on September 15, 2025, under the Aging Research program (CFDA 93.866) to support research on epitranscriptomic regulation of microglia in Alzheimer's disease. The research investigates how m6a methylation of adenosine residues in messenger RNA regulates microglial cell function and transitions between resting and activated states during Alzheimer's disease pathogenesis, with the goal of identifying novel...
- The National Institute on Aging awarded The Administrators of Tulane Educational Fund (Tulane University) $871,998 on August 1, 2026, under the Aging Research program (CFDA 93.866) to investigate accelerated aging in the central nervous system of SIV-infected macaques. The research focuses on astrocyte dysfunction as a central mechanism driving HIV-associated accelerated aging and cognitive decline. The study examines how activated astrocytes in brain regions increase leukocyte transmigration...
- The National Institute on Aging awarded The Washington University $642,991 on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate genetic drivers of phenotypic variability in autosomal dominant Alzheimer's disease using a multi-omics approach. The research identifies genetic alterations associated with Alzheimer's disease risk and presentation in individuals carrying mutations in the PSEN1, APP, and PSEN2 genes. The project characterizes transcriptomic brain profiles...
- The National Institute on Aging awarded the Translational Genomics Research Institute $123,066 on July 1, 2026, under the Aging Research program (CFDA 93.866) to identify molecular differences between Lewy body disease and Alzheimer's disease through multi-omics analysis. The recipient will characterize transcriptomic and genomic alterations in postmortem anterior cingulate cortex tissue from 607 neuropathologically defined cases, including those with Lewy body disease, Alzheimer's disease,...